drugset / Trial / NCT03419650
Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)
NaSingle-groupOpen-labelTreatment
Summary
Demonstrate the clinical value of Acthar TM in patients with active Psoriatic Arthritis who lack adequate response to DMARDS, and the quantification of response by clinical, serologic and structural parameters.
Timeline
- Start
- 2018-07-20
- Primary completion
- 2021-08-25
- Completion
- 2021-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acthar | Peptide | 40 iu | — |